Researchers have been struggling with getting quality materials to help them in accomplishing certain tasks. Oncotarget has played a major role in availing different materials to help these people come up with quality findings and raise the standards of their research. Students in different scientific fields including those in medical fields have found very useful journals from Oncotarget that have helped them to do their work.
How Oncotarget has increased the availability of scientific journals
Several scientists have written some research work but availing these resources has been a problem. Oncotarget is an organization that helps different people to get these resources without having to pay anything. The major problem facing research work in the current institutions is the failure to raise enough money to purchase the required journals. Through the efforts made by Oncotarget, these resources can now be accessed without any charges. The move has helped serious researchers to get their documents at any time.
Currently, the organization is made of a team of experts who are willing to help other scientists to reach their goals. Having been in the scientific field, the leaders understand the challenges that face scientific research, and for this reason, they are dedicated to making the process easy for them. The leaders have the desire to give out materials that can increase the influence of science in the contemporary world. There are several challenges in the medical field like the need to understand different therapies. With their involvement, there has been a bit of relief in the last couple of years. Learn more at researchgate.net
The popularity increase through the impact factor
Since Oncotarget was founded in 2010, it has been providing help to several scientists. Their consistency in providing help has increased their popularity since the beginning of their operation. In 2011, only about 493 resources were cited. The impact factor at this time was 4.7. The figures have constantly been increasing to the current impact factor of 5.1. At the moment, more that 30000 resources have been cited and the popularity is rapidly rising. With their continued support, the organization is likely to reach more scientists in the world and increase the quality of scientific research.
Dr. Siegall Clay is the current serving CEO, President, and Co-founder of Seattle Genetics. He has worked in different research institutes and organizations, before co-founding Seattle Genetics. He attained his B.S in Zoology from Maryland University, and later on a Ph.D. specializing in Genetics from George Washington University. He also serves on the board of Directors in two different private companies, Mirna Therapeutics, and Alder Biopharmaceuticals. He kicked off his career serving at National Institutes of Health from the year 1988 to 1991 and later worked at Bristol-Myers Squibb pharmaceutical Research Institute from the year 1991 to 1997.
Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.
Seattle Genetics was founded in the year 1998, with Dr. Siegall as the President. The company is a biotechnology company that works on developing preclinical and clinical products, and research that is devoted to Cancer research. The company has earned good reputation over the years as the leading antibody technologies. His leadership has helped the company attain numerous strategic licenses with its technology. The licenses include Abvie, Pfizer, and Genentech (Roche), generating over 300$ million Dollar in revenue, since its inception. Seattle Genetics technology has earned and maintained a huge share in the clinical development programs, having over 20 ADCs in the development of clinical products all across the program.
Prior to Seattle Genetics getting numerous collaborations, the company achieved an exclusive international strategic collaboration agreement with Genentech worth over $860 million for SGN-40. The ADCs technology is designed to not affect non-targeted cells. It has worked to reduce the numerous side effects that came with the traditional Chemotherapy but also maintaining high antitumor activity. The company leads in ADCs with their program ADCETRIS (brentuximab vedotin), which opened a new class in the ADCs technologies. Not only is the program broad and recommended for clinical development programs but also runs a huge potential of soon becoming the foundation for treatment of Hodgkin Lymphoma, B-cell lymphomas, CD-30 expressing lymphomas, and B-cell lymphomas.
The collaboration with Takeda helped Seattle Genetics achieve full rights with its ADCETRIS program in both Canada and the United States. Takeda has the upper hand in the commercialization rights, maintaining them exclusively in all other countries.